Pemetrexed and Epilepsy aggravated - a phase IV clinical study of FDA data

Summary:

Epilepsy aggravated is reported as a side effect among people who take Pemetrexed (pemetrexed), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Alimta, and have Non-small cell lung cancer metastatic.

The phase IV clinical study analyzes which people have Epilepsy aggravated when taking Pemetrexed. It is created by eHealthMe based on reports of 17,478 people who have side effects when taking Pemetrexed from the FDA, and is updated regularly.

What is Pemetrexed?

Pemetrexed has active ingredients of pemetrexed. eHealthMe is studying from 17,491 Pemetrexed users. Check the latest studies of Pemetrexed.

What is Epilepsy aggravated?

Epilepsy aggravated (serious common and diverse set of chronic neurological disorders characterized by seizures) is found to be associated with 1,070 drugs and 456 conditions by eHealthMe. Check the latest studies of Epilepsy aggravated.

On Jul, 14, 2026

17,478 people reported to have side effects when taking Pemetrexed.
Among them, 17 people (0.1%) have Epilepsy aggravated.

Could Pemetrexed cause Epilepsy aggravated?

Among these 17 people:

How long have people been on Pemetrexed when they have Epilepsy aggravated? *

What is the gender of people who have Epilepsy aggravated when taking Pemetrexed? *

female: 50 %
male: 50 %

What is the age of people who have Epilepsy aggravated when taking Pemetrexed? *

What are other drugs people take besides Pemetrexed? *

What are other side effects people have besides Epilepsy aggravated? *

Weakness: 4 people, 23.53%
Fatigue (feeling of tiredness): 4 people, 23.53%
General Physical Health Deterioration (weak health status): 4 people, 23.53%
Oedema (fluid collection in tissue): 4 people, 23.53%
Inflammation: 4 people, 23.53%
Malignant Neoplasm Progression (cancer tumour came back): 4 people, 23.53%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 3 people, 17.65%
Metastases To Lung (cancer spreads to lung): 2 people, 11.76%
Cerebral Ischaemia (insufficient blood flow to the brain to meet metabolic demand): 2 people, 11.76%
Metastases To Bone (cancer spreads to bone): 2 people, 11.76%

What are the existing conditions these people have? *

Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 7 people, 41.18%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 23.53%
Metastases To Lymph Nodes (cancer spreads to lymph node): 2 people, 11.76%
Pain: 1 person, 5.88%
Brain Oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain): 1 person, 5.88%
Breast Cancer: 1 person, 5.88%
Depression: 1 person, 5.88%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 1 person, 5.88%
Lung Adenocarcinoma Stage Iv (the cancer has spread to other organs of the body, such as the other lung, brain, or liver): 1 person, 5.88%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Pemetrexed and have Epilepsy aggravated?

- Check whether Epilepsy aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pemetrexed:

Pemetrexed (17,491 reports)

Browse all side effects of Pemetrexed:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Epilepsy aggravated:

Epilepsy aggravated (1,071 drugs)

Browse all the conditions that are associated with Epilepsy aggravated:

Epilepsy aggravated (456 conditions)

Related publications that referenced our studies

Gota V, Kavathiya K, Doshi K, Gurjar M, Damodaran SE, Noronha V, Joshi A, Prabhash K, "High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy", Cancer management and research, 2017 Jan .
Gota V, Kavathiya K, Doshi K, Gurjar M, Damodaran SE, Noronha V, Joshi A, Prabhash K, "High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy", Cancer management and research, 2017 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on pemetrexed (the active ingredients of Pemetrexed) and Pemetrexed (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.